The stock of Outlook Therapeutics Inc (OTLK) has gone down by -2.09% for the week, with a 5.81% rise in the past month and a 5.13% rise in the past quarter. The volatility ratio for the week is 2.57%, and the volatility levels for the past 30 days are 7.45% for OTLK. The simple moving average for the last 20 days is 2.05% for OTLK stock, with a simple moving average of -52.65% for the last 200 days.
Is It Worth Investing in Outlook Therapeutics Inc (NASDAQ: OTLK) Right Now?
The 36-month beta value for OTLK is also noteworthy at 0.27. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for OTLK is 21.11M, and at present, short sellers hold a 16.97% of that float. The average trading volume of OTLK on May 23, 2025 was 425.75K shares.
OTLK) stock’s latest price update
Outlook Therapeutics Inc (NASDAQ: OTLK)’s stock price has increased by 0.61 compared to its previous closing price of 1.63. However, the company has seen a -2.09% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-22 that ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Analysts’ Opinion of OTLK
BTIG Research, on the other hand, stated in their research note that they expect to see OTLK reach a price target of $50. The rating they have provided for OTLK stocks is “Buy” according to the report published on March 27th, 2024.
Chardan Capital Markets gave a rating of “Buy” to OTLK, setting the target price at $3 in the report published on February 15th of the previous year.
OTLK Trading at 11.60% from the 50-Day Moving Average
After a stumble in the market that brought OTLK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.27% of loss for the given period.
Volatility was left at 7.45%, however, over the last 30 days, the volatility rate increased by 2.57%, as shares surge +5.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.49% upper at present.
During the last 5 trading sessions, OTLK fell by -2.09%, which changed the moving average for the period of 200-days by -76.74% in comparison to the 20-day moving average, which settled at $1.6070. In addition, Outlook Therapeutics Inc saw -13.23% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OTLK starting from KENYON LAWRENCE A, who purchase 5,000 shares at the price of $5.69 back on Sep 26 ’24. After this action, KENYON LAWRENCE A now owns 5,946 shares of Outlook Therapeutics Inc, valued at $28,446 using the latest closing price.
Stock Fundamentals for OTLK
The total capital return value is set at 2.16.
Based on Outlook Therapeutics Inc (OTLK), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -100.78. The debt to equity ratio resting at -0.01. The interest coverage ratio of the stock is -669.74.
Currently, EBITDA for the company is -71.59 million with net debt to EBITDA at 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.72.
Conclusion
In summary, Outlook Therapeutics Inc (OTLK) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
